{"pmid":32471856,"title":"Introductions and early spread of SARS-CoV-2 in the New York City area.","text":["Introductions and early spread of SARS-CoV-2 in the New York City area.","New York City (NYC) has emerged as one of the epicenters of the current SARS-CoV-2 pandemic. To identify the early transmission events underlying the rapid spread of the virus in the NYC metropolitan area, we sequenced the virus causing COVID-19 in patients seeking care at the Mount Sinai Health System. Phylogenetic analysis of 84 distinct SARS-CoV2 genomes indicates multiple, independent but isolated introductions mainly from Europe and other parts of the United States. Moreover, we find evidence for community transmission of SARS-CoV-2 as suggested by clusters of related viruses found in patients living in different neighborhoods of the city.","Science","Gonzalez-Reiche, Ana S","Hernandez, Matthew M","Sullivan, Mitchell J","Ciferri, Brianne","Alshammary, Hala","Obla, Ajay","Fabre, Shelcie","Kleiner, Giulio","Polanco, Jose","Khan, Zenab","Alburquerque, Bremy","van de Guchte, Adriana","Dutta, Jayeeta","Francoeur, Nancy","Melo, Betsaida Salom","Oussenko, Irina","Deikus, Gintaras","Soto, Juan","Sridhar, Shwetha Hara","Wang, Ying-Chih","Twyman, Kathryn","Kasarskis, Andrew","Altman, Deena R","Smith, Melissa","Sebra, Robert","Aberg, Judith","Krammer, Florian","Garcia-Sastre, Adolfo","Luksza, Marta","Patel, Gopi","Paniz-Mondolfi, Alberto","Gitman, Melissa","Sordillo, Emilia Mia","Simon, Viviana","van Bakel, Harm","32471856"],"abstract":["New York City (NYC) has emerged as one of the epicenters of the current SARS-CoV-2 pandemic. To identify the early transmission events underlying the rapid spread of the virus in the NYC metropolitan area, we sequenced the virus causing COVID-19 in patients seeking care at the Mount Sinai Health System. Phylogenetic analysis of 84 distinct SARS-CoV2 genomes indicates multiple, independent but isolated introductions mainly from Europe and other parts of the United States. Moreover, we find evidence for community transmission of SARS-CoV-2 as suggested by clusters of related viruses found in patients living in different neighborhoods of the city."],"journal":"Science","authors":["Gonzalez-Reiche, Ana S","Hernandez, Matthew M","Sullivan, Mitchell J","Ciferri, Brianne","Alshammary, Hala","Obla, Ajay","Fabre, Shelcie","Kleiner, Giulio","Polanco, Jose","Khan, Zenab","Alburquerque, Bremy","van de Guchte, Adriana","Dutta, Jayeeta","Francoeur, Nancy","Melo, Betsaida Salom","Oussenko, Irina","Deikus, Gintaras","Soto, Juan","Sridhar, Shwetha Hara","Wang, Ying-Chih","Twyman, Kathryn","Kasarskis, Andrew","Altman, Deena R","Smith, Melissa","Sebra, Robert","Aberg, Judith","Krammer, Florian","Garcia-Sastre, Adolfo","Luksza, Marta","Patel, Gopi","Paniz-Mondolfi, Alberto","Gitman, Melissa","Sordillo, Emilia Mia","Simon, Viviana","van Bakel, Harm"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471856","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1126/science.abc1917","locations":["New York","United States","New York"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Transmission","Prevention","Mechanism"],"weight":1,"_version_":1668255193280544768,"score":9.490897,"similar":[{"pmid":32407306,"title":"Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak - New York City, March 11-May 2, 2020.","text":["Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak - New York City, March 11-May 2, 2020.","SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first identified in December 2019 in Wuhan, China, and has since spread worldwide. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic (1). That same day, the first confirmed COVID-19-associated fatality occurred in New York City (NYC). To identify confirmed COVID-19-associated deaths, defined as those occurring in persons with laboratory-confirmed SARS-CoV-2 infection, on March 13, 2020, the New York City Department of Health and Mental Hygiene (DOHMH) initiated a daily match between all deaths reported to the DOHMH electronic vital registry system (eVital) (2) and laboratory-confirmed cases of COVID-19. Deaths for which COVID-19, SARS-CoV-2, or an equivalent term is listed on the death certificate as an immediate, underlying, or contributing cause of death, but that do not have laboratory-confirmation of COVID-19 are classified as probable COVID-19-associated deaths. As of May 2, a total of 13,831 laboratory-confirmed COVID-19-associated deaths, and 5,048 probable COVID-19-associated deaths were recorded in NYC (3). Counting only confirmed or probable COVID-19-associated deaths, however, likely underestimates the number of deaths attributable to the pandemic. The counting of confirmed and probable COVID-19-associated deaths might not include deaths among persons with SARS-CoV-2 infection who did not access diagnostic testing, tested falsely negative, or became infected after testing negative, died outside of a health care setting, or for whom COVID-19 was not suspected by a health care provider as a cause of death. The counting of confirmed and probable COVID-19-associated deaths also does not include deaths that are not directly associated with SARS-CoV-2 infection. The objective of this report is to provide an estimate of all-cause excess deaths that have occurred in NYC in the setting of widespread community transmission of SARS-CoV-2. Excess deaths refer to the number of deaths above expected seasonal baseline levels, regardless of the reported cause of death. Estimation of all-cause excess deaths is used as a nonspecific measure of the severity or impact of pandemics (4) and public health emergencies (5). Reporting of excess deaths might provide a more accurate measure of the impact of the pandemic.","MMWR Morb Mortal Wkly Rep","32407306"],"abstract":["SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first identified in December 2019 in Wuhan, China, and has since spread worldwide. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic (1). That same day, the first confirmed COVID-19-associated fatality occurred in New York City (NYC). To identify confirmed COVID-19-associated deaths, defined as those occurring in persons with laboratory-confirmed SARS-CoV-2 infection, on March 13, 2020, the New York City Department of Health and Mental Hygiene (DOHMH) initiated a daily match between all deaths reported to the DOHMH electronic vital registry system (eVital) (2) and laboratory-confirmed cases of COVID-19. Deaths for which COVID-19, SARS-CoV-2, or an equivalent term is listed on the death certificate as an immediate, underlying, or contributing cause of death, but that do not have laboratory-confirmation of COVID-19 are classified as probable COVID-19-associated deaths. As of May 2, a total of 13,831 laboratory-confirmed COVID-19-associated deaths, and 5,048 probable COVID-19-associated deaths were recorded in NYC (3). Counting only confirmed or probable COVID-19-associated deaths, however, likely underestimates the number of deaths attributable to the pandemic. The counting of confirmed and probable COVID-19-associated deaths might not include deaths among persons with SARS-CoV-2 infection who did not access diagnostic testing, tested falsely negative, or became infected after testing negative, died outside of a health care setting, or for whom COVID-19 was not suspected by a health care provider as a cause of death. The counting of confirmed and probable COVID-19-associated deaths also does not include deaths that are not directly associated with SARS-CoV-2 infection. The objective of this report is to provide an estimate of all-cause excess deaths that have occurred in NYC in the setting of widespread community transmission of SARS-CoV-2. Excess deaths refer to the number of deaths above expected seasonal baseline levels, regardless of the reported cause of death. Estimation of all-cause excess deaths is used as a nonspecific measure of the severity or impact of pandemics (4) and public health emergencies (5). Reporting of excess deaths might provide a more accurate measure of the impact of the pandemic."],"journal":"MMWR Morb Mortal Wkly Rep","date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407306","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.15585/mmwr.mm6919e5","locations":["Wuhan","China","New York"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666802845285875712,"score":239.14195},{"pmid":32463802,"title":"New York City COVID-19 resident physician exposure during exponential phase of pandemic.","text":["New York City COVID-19 resident physician exposure during exponential phase of pandemic.","BackgroundFrom March 2-April 12, 2020, New York City (NYC) experienced exponential growth of the COVID-19 pandemic due to novel coronavirus (SARS-CoV-2). Little is known regarding how physicians have been affected. We aimed to characterize COVID-19 impact on NYC resident physicians.MethodsIRB-exempt and expedited cross-sectional analysis through survey to NYC residency program directors (PDs) April 3-12, 2020, encompassing events from March 2-April 12, 2020.ResultsFrom an estimated 340 residency programs around NYC, recruitment yielded 91 responses, representing 24 specialties and 2,306 residents. 45.1% of programs reported at least one resident with confirmed COVID-19: 101 resident physicians were confirmed COVID-19-positive, with an additional 163 residents presumed positive for COVID-19 based on symptoms but awaiting or unable to obtain testing. Two COVID-19-positive residents were hospitalized, with one in intensive care. Among specialties with >100 residents represented, negative binomial regression indicated that infection risk differed by specialty (p=0.039). 80% of programs reported quarantining a resident. 90/91 programs reported reuse or extended mask use, and 43 programs reported that personal protective equipment (PPE) was suboptimal. 65 programs (74.7%) have redeployed residents elsewhere to support COVID-19 efforts.ConclusionMany resident physicians around NYC have been affected by COVID-19 through direct infection, quarantine, or redeployment. Lack of access to testing and concern regarding suboptimal PPE are common among residency programs. Infection risk may differ by specialty.FundingAHA, MPB, RWSC, CGM, LRDG, JDH: NEI Core Grant P30EY019007, RPB Unrestricted Grant. ACP and JS: Parker Family Chair. SXX: University of Pennsylvania.","J Clin Invest","Breazzano, Mark P","Shen, Junchao","Abdelhakim, Aliaa H","Dagi Glass, Lora","Horowitz, Jason","Xie, Sharon X","De Moraes, C Gustavo","Chen-Plotkin, Alice","Chen, Royce Ws","32463802"],"abstract":["BackgroundFrom March 2-April 12, 2020, New York City (NYC) experienced exponential growth of the COVID-19 pandemic due to novel coronavirus (SARS-CoV-2). Little is known regarding how physicians have been affected. We aimed to characterize COVID-19 impact on NYC resident physicians.MethodsIRB-exempt and expedited cross-sectional analysis through survey to NYC residency program directors (PDs) April 3-12, 2020, encompassing events from March 2-April 12, 2020.ResultsFrom an estimated 340 residency programs around NYC, recruitment yielded 91 responses, representing 24 specialties and 2,306 residents. 45.1% of programs reported at least one resident with confirmed COVID-19: 101 resident physicians were confirmed COVID-19-positive, with an additional 163 residents presumed positive for COVID-19 based on symptoms but awaiting or unable to obtain testing. Two COVID-19-positive residents were hospitalized, with one in intensive care. Among specialties with >100 residents represented, negative binomial regression indicated that infection risk differed by specialty (p=0.039). 80% of programs reported quarantining a resident. 90/91 programs reported reuse or extended mask use, and 43 programs reported that personal protective equipment (PPE) was suboptimal. 65 programs (74.7%) have redeployed residents elsewhere to support COVID-19 efforts.ConclusionMany resident physicians around NYC have been affected by COVID-19 through direct infection, quarantine, or redeployment. Lack of access to testing and concern regarding suboptimal PPE are common among residency programs. Infection risk may differ by specialty.FundingAHA, MPB, RWSC, CGM, LRDG, JDH: NEI Core Grant P30EY019007, RPB Unrestricted Grant. ACP and JS: Parker Family Chair. SXX: University of Pennsylvania."],"journal":"J Clin Invest","authors":["Breazzano, Mark P","Shen, Junchao","Abdelhakim, Aliaa H","Dagi Glass, Lora","Horowitz, Jason","Xie, Sharon X","De Moraes, C Gustavo","Chen-Plotkin, Alice","Chen, Royce Ws"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463802","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1172/JCI139587","keywords":["covid-19","epidemiology"],"locations":["New York","New York"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1668079521334558720,"score":227.09698},{"pmid":32386545,"title":"Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.","text":["Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.","The novel coronavirus SARS-CoV-2 was first detected in the Pacific Northwest region of the United States in January 2020, with subsequent COVID-19 outbreaks detected in all 50 states by early March. To uncover the sources of SARS-CoV-2 introductions and patterns of spread within the United States, we sequenced nine viral genomes from early reported COVID-19 patients in Connecticut. Our phylogenetic analysis places the majority of these genomes with viruses sequenced from Washington state. By coupling our genomic data with domestic and international travel patterns, we show that early SARS-CoV-2 transmission in Connecticut was likely driven by domestic introductions. Moreover, the risk of domestic importation to Connecticut exceeded that of international importation by mid-March regardless of our estimated effects of federal travel restrictions. This study provides evidence of widespread sustained transmission of SARS-CoV-2 within the United States and highlights the critical need for local surveillance.","Cell","Fauver, Joseph R","Petrone, Mary E","Hodcroft, Emma B","Shioda, Kayoko","Ehrlich, Hanna Y","Watts, Alexander G","Vogels, Chantal B F","Brito, Anderson F","Alpert, Tara","Muyombwe, Anthony","Razeq, Jafar","Downing, Randy","Cheemarla, Nagarjuna R","Wyllie, Anne L","Kalinich, Chaney C","Ott, Isabel M","Quick, Joshua","Loman, Nicholas J","Neugebauer, Karla M","Greninger, Alexander L","Jerome, Keith R","Roychoudhury, Pavitra","Xie, Hong","Shrestha, Lasata","Huang, Meei-Li","Pitzer, Virginia E","Iwasaki, Akiko","Omer, Saad B","Khan, Kamran","Bogoch, Isaac I","Martinello, Richard A","Foxman, Ellen F","Landry, Marie L","Neher, Richard A","Ko, Albert I","Grubaugh, Nathan D","32386545"],"abstract":["The novel coronavirus SARS-CoV-2 was first detected in the Pacific Northwest region of the United States in January 2020, with subsequent COVID-19 outbreaks detected in all 50 states by early March. To uncover the sources of SARS-CoV-2 introductions and patterns of spread within the United States, we sequenced nine viral genomes from early reported COVID-19 patients in Connecticut. Our phylogenetic analysis places the majority of these genomes with viruses sequenced from Washington state. By coupling our genomic data with domestic and international travel patterns, we show that early SARS-CoV-2 transmission in Connecticut was likely driven by domestic introductions. Moreover, the risk of domestic importation to Connecticut exceeded that of international importation by mid-March regardless of our estimated effects of federal travel restrictions. This study provides evidence of widespread sustained transmission of SARS-CoV-2 within the United States and highlights the critical need for local surveillance."],"journal":"Cell","authors":["Fauver, Joseph R","Petrone, Mary E","Hodcroft, Emma B","Shioda, Kayoko","Ehrlich, Hanna Y","Watts, Alexander G","Vogels, Chantal B F","Brito, Anderson F","Alpert, Tara","Muyombwe, Anthony","Razeq, Jafar","Downing, Randy","Cheemarla, Nagarjuna R","Wyllie, Anne L","Kalinich, Chaney C","Ott, Isabel M","Quick, Joshua","Loman, Nicholas J","Neugebauer, Karla M","Greninger, Alexander L","Jerome, Keith R","Roychoudhury, Pavitra","Xie, Hong","Shrestha, Lasata","Huang, Meei-Li","Pitzer, Virginia E","Iwasaki, Akiko","Omer, Saad B","Khan, Kamran","Bogoch, Isaac I","Martinello, Richard A","Foxman, Ellen F","Landry, Marie L","Neher, Richard A","Ko, Albert I","Grubaugh, Nathan D"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32386545","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cell.2020.04.021","keywords":["covid-19","minion sequencing","sars-cov-2","coronavirus","genomic epidemiology","phylogenetics","travel risk"],"locations":["United States","United States","Connecticut","Washington","Connecticut","Connecticut","United States","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Transmission","Prevention"],"weight":1,"_version_":1666428892577005570,"score":199.66606},{"pmid":32298250,"title":"Geographic Differences in COVID-19 Cases, Deaths, and Incidence - United States, February 12-April 7, 2020.","text":["Geographic Differences in COVID-19 Cases, Deaths, and Incidence - United States, February 12-April 7, 2020.","Community transmission of coronavirus disease 2019 (COVID-19) was first detected in the United States in February 2020. By mid-March, all 50 states, the District of Columbia (DC), New York City (NYC), and four U.S. territories had reported cases of COVID-19. This report describes the geographic distribution of laboratory-confirmed COVID-19 cases and related deaths reported by each U.S. state, each territory and freely associated state,* DC, and NYC during February 12-April 7, 2020, and estimates cumulative incidence for each jurisdiction. In addition, it projects the jurisdiction-level trajectory of this pandemic by estimating case doubling times on April 7 and changes in cumulative incidence during the most recent 7-day period (March 31-April 7). As of April 7, 2020, a total of 395,926 cases of COVID-19, including 12,757 related deaths, were reported in the United States. Cumulative COVID-19 incidence varied substantially by jurisdiction, ranging from 20.6 cases per 100,000 in Minnesota to 915.3 in NYC. On April 7, national case doubling time was approximately 6.5 days, although this ranged from 5.5 to 8.0 days in the 10 jurisdictions reporting the most cases. Absolute change in cumulative incidence during March 31-April 7 also varied widely, ranging from an increase of 8.3 cases per 100,000 in Minnesota to 418.0 in NYC. Geographic differences in numbers of COVID-19 cases and deaths, cumulative incidence, and changes in incidence likely reflect a combination of jurisdiction-specific epidemiologic and population-level factors, including 1) the timing of COVID-19 introductions; 2) population density; 3) age distribution and prevalence of underlying medical conditions among COVID-19 patients (1-3); 4) the timing and extent of community mitigation measures; 5) diagnostic testing capacity; and 6) public health reporting practices. Monitoring jurisdiction-level numbers of COVID-19 cases, deaths, and changes in incidence is critical for understanding community risk and making decisions about community mitigation, including social distancing, and strategic health care resource allocation.","MMWR Morb Mortal Wkly Rep","32298250"],"abstract":["Community transmission of coronavirus disease 2019 (COVID-19) was first detected in the United States in February 2020. By mid-March, all 50 states, the District of Columbia (DC), New York City (NYC), and four U.S. territories had reported cases of COVID-19. This report describes the geographic distribution of laboratory-confirmed COVID-19 cases and related deaths reported by each U.S. state, each territory and freely associated state,* DC, and NYC during February 12-April 7, 2020, and estimates cumulative incidence for each jurisdiction. In addition, it projects the jurisdiction-level trajectory of this pandemic by estimating case doubling times on April 7 and changes in cumulative incidence during the most recent 7-day period (March 31-April 7). As of April 7, 2020, a total of 395,926 cases of COVID-19, including 12,757 related deaths, were reported in the United States. Cumulative COVID-19 incidence varied substantially by jurisdiction, ranging from 20.6 cases per 100,000 in Minnesota to 915.3 in NYC. On April 7, national case doubling time was approximately 6.5 days, although this ranged from 5.5 to 8.0 days in the 10 jurisdictions reporting the most cases. Absolute change in cumulative incidence during March 31-April 7 also varied widely, ranging from an increase of 8.3 cases per 100,000 in Minnesota to 418.0 in NYC. Geographic differences in numbers of COVID-19 cases and deaths, cumulative incidence, and changes in incidence likely reflect a combination of jurisdiction-specific epidemiologic and population-level factors, including 1) the timing of COVID-19 introductions; 2) population density; 3) age distribution and prevalence of underlying medical conditions among COVID-19 patients (1-3); 4) the timing and extent of community mitigation measures; 5) diagnostic testing capacity; and 6) public health reporting practices. Monitoring jurisdiction-level numbers of COVID-19 cases, deaths, and changes in incidence is critical for understanding community risk and making decisions about community mitigation, including social distancing, and strategic health care resource allocation."],"journal":"MMWR Morb Mortal Wkly Rep","date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298250","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.15585/mmwr.mm6915e4","locations":["United States","New York","USA","USA","United States","Minnesota","Minnesota"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666138493284253696,"score":198.79709},{"pmid":32365287,"title":"Emergency department COVID management policies: one institution's experience and lessons learned.","text":["Emergency department COVID management policies: one institution's experience and lessons learned.","Coronavirus disease (COVID-19), caused by the SARS-CoV-2 virus, originated in Wuhan, Hubei Province, China in late 2019 and grew rapidly into a pandemic. As of the writing of this monograph, there are over 2 million confirmed cases worldwide and 147,000 deaths. New York City, with over 120,000 COVID-19-positive patients and over 11,000 deaths, has become the infection epicenter in the United States. The Mount Sinai Health System, with 8 hospitals spread across New York City and Long Island, has been on the forefront of the pandemic. This compendium summarizes the lessons learned through interdisciplinary collaborations to meet the varied challenges created by the explosive appearance of the infection in our community, and will be updated continuously as new research and best practices emerge. It is our hope is that the collaborations and lessons learned that went into creating these guidelines and protocols can serve as a useful template for other systems to adapt to their fight against COVID-19.","Emerg Med Pract","Leibner, Evan S","Stokes, Sonya","Ahmad, Danish","Legome, Eric","32365287"],"abstract":["Coronavirus disease (COVID-19), caused by the SARS-CoV-2 virus, originated in Wuhan, Hubei Province, China in late 2019 and grew rapidly into a pandemic. As of the writing of this monograph, there are over 2 million confirmed cases worldwide and 147,000 deaths. New York City, with over 120,000 COVID-19-positive patients and over 11,000 deaths, has become the infection epicenter in the United States. The Mount Sinai Health System, with 8 hospitals spread across New York City and Long Island, has been on the forefront of the pandemic. This compendium summarizes the lessons learned through interdisciplinary collaborations to meet the varied challenges created by the explosive appearance of the infection in our community, and will be updated continuously as new research and best practices emerge. It is our hope is that the collaborations and lessons learned that went into creating these guidelines and protocols can serve as a useful template for other systems to adapt to their fight against COVID-19."],"journal":"Emerg Med Pract","authors":["Leibner, Evan S","Stokes, Sonya","Ahmad, Danish","Legome, Eric"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32365287","source":"PubMed","week":"202019|May 04 - May 10","locations":["Wuhan","Hubei","China","New York","United States","New York"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138495976996865,"score":192.86172}]}